We are living through a ballooning mental health crisis. Over 1 billion people experience mental illness globally, including one in five Americans who suffer from anxiety or depression. For many of these patients, existing treatments are not enough, with nearly a third of patients considered treatment-resistant and 60-75% unable to achieve complete remission.
Every 40 Seconds
How often someone dies from (and 20 others attempt) suicide (WHO)
11% - 42%
The percentage growth of those who reported anxiety or depression from 2020 to 2021 (CDC)
Combined global sufferers of anxiety and depression, the two most prevalent mental health conditions (WHO)
The global cost of treating the mental health crisis by 2030, up from $2.5 trillion in 2010 (WEF)
Current pharmacological treatments for depression and anxiety can carry serious side effects and risks, work marginally or not at all for some patients. Historically, research and development of these drugs often focuses on a handful of targets, so they present similar drawbacks or side effects. The recent renaissance of psychedelics—a class of psychoactive molecules that produces changes in perception, mood, and cognitive processes—is opening a world of options for people with resistant mental health disorders, but adapting these medicines to the modern healthcare framework brings challenges of its own.
At Sensorium, our approach to treating mental health disorders leverages knowledge about what has worked in human populations for centuries to create scalable and broadly useful small molecules capable of transforming the current paradigm.
This approach is how we discover new mechanisms, cultivate new solutions, and offer new hope.
Because it’s time to go beyond just surviving, to thriving.